Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Annexon Biosciences logo — Unlocking the Next Generation of Complement Therapies

Annexon Biosciences

Unlocking the Next Generation of Complement Therapies

Founded 2011 United States South San Francisco, United States 111 employees IPO Total: $709.00M Biotechnology, Health Care +3

General Information

Company Name Annexon Biosciences
Founded Year 2011
Location United States South San Francisco, United States +1
Founders / Decision Makers
Team member
Employees 111
Industries Biotechnology, Health Care, Health and Wellness +2
Funding Stage IPO
Social

Get notified when Annexon Biosciences moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Annexon Biosciences

Annexon Biosciences is a clinical-stage biopharmaceutical company founded in 2011, with a focus on developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. The company's pipeline consists of innovative product candidates, namely ANX005 for intravenous administration, ANX007 for intravitreal administration, and ANX009 for subcutaneous administration, all designed to block the activity of C1q and the entire classical complement pathway. Annexon is leveraging a disciplined, biomarker-driven strategy to enhance the probability of technical success of its portfolio. The company recently received a noteworthy $125.00MPost-IPO Equity investment at 20 December 2023. Annexon's mission revolves around "Unlocking the Next Generation of Complement Therapies", and its efforts are centered in the United States. For more information, visit www.annexonbio.com.

Taxonomy: biopharmaceutical, complement therapies, clinical-stage, autoimmune disorders, neurodegenerative disorders, ophthalmic disorders, pipeline, platform technology, C1q, classical complement pathway, product candidates, biomarker-driven strategy, intravenous administration, intravitreal administration, subcutaneous administration

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post Ipo Equity •••••• - 01 Nov 2025
Post Ipo Equity •••••• - 01 Jun 2024
Post Ipo Equity •••••• - 01 Dec 2023
Private Placement Vc •••••• - 01 Jul 2022
IPO •••••• 12
Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		01 Jul 2020

View All 10 Funding Rounds

Annexon Biosciences Alternatives & Competitors

Annexon Biosciences vs
Montis Biosciences
Montis Biosciences Belgium

Pioneering next-gen therapeutics to harness C1q's central role in neuroinflammatory diseases.

Unknown
15 employees
Biotechnology, Health and Wellness
Compare Annexon Biosciences vs Montis Biosciences
Annexon Biosciences vs
True North Therapeutics
True North Therapeutics

True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement...

Series Unknown
2 employees
Biotechnology, Health Care
Compare Annexon Biosciences vs True North Therapeutics
Annexon Biosciences vs
Locanabio, Inc.
Locanabio, Inc. United States

Creating RNA-targeting gene therapies to treat devastating diseases

Series B
7 employees
Biotechnology, Health Care
Compare Annexon Biosciences vs Locanabio, Inc.

FAQ About Annexon Biosciences

Unlocking the Next Generation of Complement Therapies
Annexon Biosciences was founded in 2011.
Annexon Biosciences is headquartered in South San Francisco, United States.
Annexon Biosciences operates in the following industries: Biotechnology, Health Care, Health and Wellness, Life Sciences, Pharmaceutical.
Annexon Biosciences has approximately 111 employees.
Annexon Biosciences has completed 10 funding rounds, raising a total of $709.00M. The latest funding stage is IPO.
Top alternatives and competitors to Annexon Biosciences include Montis Biosciences, True North Therapeutics, Locanabio, Inc., NexImmune, Inc., Liposeuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Annexon Biosciences and Montis Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Annexon Biosciences and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy